J Neuroophthalmol. 2019 Sep;39(3):352-359. doi: 10.1097/WNO.0000000000000837.
Migraine is very common. In addition to affecting visual quality of life, migraine can be seen in the neuro-ophthalmology office with regularity. Treatment is critical to assist in the reduction of disability and symptoms. Knowing the evidence-based new treatments is important for every neuro-ophthalmologist.
Using PubMed, and using the term migraine as it related to the terms treatment, evidence-based, calcitonin gene-related peptide (CGRP) inhibitor or antibody, electrical stimulation, vagal nerve stimulation, a literature review was performed.
Aside from standard well-described and evidence-based therapies for the acute treatment and prevention of migraine, many new therapies have received FDA approval. In this review, we summarize the contribution of new classes of migraine-specific therapies: CGRP antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) for prevention and inhibitors referred to as gepants (ubrogepant and rimegepant) for acute treatment. We also cover newer medications about to be approved, such as lasmitiditan. Devices, including the hand-held vagal nerve stimulator, supraorbital stimulation, transmagnetic stimulation, and remote electrical stimulation, are now approved by the FDA for treatment of migraine.
Many new and exciting therapies exist for the treatment of migraine. Keeping up with this rapidly evolving field is important in reducing disability from the common disease of migraine.
偏头痛非常常见。除了影响视觉生活质量外，偏头痛也经常在神经眼科门诊出现。治疗对于减轻残疾和症状至关重要。了解基于证据的新治疗方法对每位神经眼科医生都很重要。
使用 PubMed，使用术语偏头痛及其相关术语，如治疗、基于证据、降钙素基因相关肽 (CGRP) 抑制剂或抗体、电刺激、迷走神经刺激，进行文献回顾。
除了偏头痛急性治疗和预防的标准描述性和基于证据的疗法外，许多新疗法已获得 FDA 批准。在这篇综述中，我们总结了偏头痛特异性治疗新类别的贡献：CGRP 抗体（erenumab、fremanezumab、galcanezumab 和 eptinezumab）用于预防和抑制剂，称为 gepants（ubrogepant 和 rimegepant）用于急性治疗。我们还介绍了即将获得批准的新型药物，如 lasmitiditan。FDA 现已批准手持式迷走神经刺激器、眶上刺激、经颅磁刺激和远程电刺激等设备用于偏头痛治疗。
偏头痛的治疗方法有很多新的令人兴奋的治疗方法。跟上这个快速发展的领域对于减轻常见疾病偏头痛引起的残疾非常重要。
